In This Section:

◄
Basic Science
Breast Cancer
COVID-19
GI Cancers
Guidelines
Haematological Cancers
Miscellaneous
Other Cancers
Radcliffe Content
Review Articles
Service Development
►

Cardio-oncology

Cardio-oncology is the cardiac care of cancer patients. Cardiac issues may develop during cancer treatment or may be pre-existing or may develop as late effects. There has been increasing recognition of these issues recently which has led to the development of the new sub-speciality of cardio-oncology bringing together cardiologists, oncologists and allied healthcare professionals.

This Cardio-oncology section showcases key papers in the field to allow readers to quickly familiarise themselves with the latest advances in this rapidly developing field. There will be work related to the different cardiac complications of cancer treatment e.g. acute coronary syndromes, myocarditis, heart failure and arrhythmias. Research focussing on specific cancer therapies and their cardiotoxicities will also be featured e.g. immunotherapies, targeted therapies, cytotoxic drugs, radiotherapy etc. Finally this section will enable the reader to reference the most up-to-date guidelines in the field from national and international organisations.

See more ▼
Close X
Other videos you might like
Dr Arjun K Ghosh

Section Advisor

Dr Arjun K Ghosh

Consultant Cardiologist, Barts Heart Centre, University College London Hospital and Hatter Cardiovascular Institute, UK

The Radcliffe cardio-oncology educational hub is an independent program led by Dr Arjun K Ghosh.

Broadcast

Cardiomuscular Biomarkers in Diagnosis & Prognostication of ICI Myocarditis

Joe Carver, Daniel Lenihan, Jose Alvarez-Cardona, et al

Watch time: 1h 2m 48s

Marianna Fontana, Julian Gillmore, Laura Obici, et al

Broadcast

Expert Insights into Challenging Cardio-Oncology Cases

Daniel Lenihan, Joe Carver, Joshua Mitchell, et al

Watch time: 1h 3m 38s

Broadcast

Prediction of Coronary Heart Disease Events

Daniel Lenihan, Joe Carver, Patricia S de Marco, et al

Watch time: 56m 27s

Broadcast

Comorbidities and Cardiovascular Risk Factors in Older Adults

Daniel Lenihan, Joe Carver, Ishwaria M Subbiah, et al

Watch time: 1h 6m 23s

Broadcast

Drug Shortages and Their Impact on Cardio-Oncology Care

Daniel Lenihan, Joe Carver, Kristen Petersen, et al

Watch time: 1h 4s

Broadcast

Outcomes by Cardiac Stage in Patients with Newly Diagnosed AL Amyloidosis

Daniel Lenihan, Joe Carver, Jose Alvarez-Cardona, et al

Watch time: 58m 45s

Broadcast

Cardiac Imaging to Detect Cardiotoxicity

Daniel Lenihan, Marielle Scherrer-Crosbie, Teresa López Fernández, et al

Watch time: 1h 7s

Broadcast

Dexrazoxane and Long-Term Heart Function in Survivors of Childhood Cancer

Jahanzaib Ekram, Jose Alvarez-Cardona, Daniel Lenihan, et al

Watch time: 53m 12s

Broadcast

Trials and Tribulations of Novel ICI Associated Myocarditis

Dominic Vickers, Daniel Chen, Charlotte Lemech, et al

Watch time: 1h 8m 6s

Broadcast

A Patient With a Cardiac Mass

Daniel Lenihan, Joe Carver, Jeanne DeCara, et al

Watch time: 1h 5m 33s

Broadcast

Implementation of the New ESC/IC-OS Cardio-Oncology Guidelines

Susan F Dent, Alexander Lyon, Teresa López Fernández, et al

Watch time: 1h 1m 13s

David G Gent , Rebecca Dobson ,

Read time: 15m

Kalliopi Keramida , Athanasios Kostoulas ,

Read time: 11m

Recent Videos

Broadcast

Cardio-oncology: The Overlap of Cardiovascular and Cancer Risk

Jessica Shank Coviello, Daniel Lenihan, Joe Carver, et al

Watch time: 1h 7m 28s

Video Series

ATTR-CM: Where Are We Now and Where to Next?

Ahmad Masri , Finn Gustafsson, Marianna Fontana, et al

Broadcast

SGLT2 Inhibitor Use and Risk of Clinical Events in Patients with CTRCD

Walter Schiffer, Jose Alvarez-Cardona, Daniel Lenihan, et al

Watch time: 1h 1m 50s

Broadcast

Venous Thromboembolism in Cancer Patients

Sergey Kozhukhov, Nataliia Dovganych, Daniel Lenihan, et al

Watch time: 1h 3m 54s

Broadcast

Tumour Board: CV Toxicity

Daniel Lenihan, Joe Carver, Teresa López Fernández, et al

Watch time: 1h 4m 16s

Broadcast

The Imminent Digital Revolution in Cardio-Oncology Research

Daniel Lenihan, Joe Carver, Julius C Heemelaar, et al

Watch time: 57m 55s

Amyloidosis and Myeloma

Dual Aortic Stenosis and Transthyretin Cardiac Amyloidosis: Do We Have Enough Evidence?

Gupta PK. JACC CardioOncol. 2022;4(1):144.

Basic Science

From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach

Minotti G et al. JACC CardioOncol. 2022;4(1):139-140.

How to Apply Translational Models to Probe Mechanisms of Cardiotoxicity

Livingston CE et al. JACC CardioOncol. 2022;4(1):130-135.

Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay

Schirone L et al. Cells. 2022;11(13):2000.

Cardiac Remodeling in Cancer-Induced Cachexia: Functional, Structural, and Metabolic Contributors

Wiggs MP et al. Cells. 2022;11(12):1931.

A Systematic Review of miRNAs As Biomarkers for Chemotherapy-Induced Cardiotoxicity in Breast Cancer Patients Reveals Potentially Clinically Informative Panels As Well as Key Challenges in miRNA Research

Brown C et al. Cardiooncology. 2022;8(1):16.

Breast Cancer

A Systematic Review and Meta-Analysis of Beta-Blockers and Renin-Angiotensin System Inhibitors for Preventing Left Ventricular Dysfunction Due to Anthracyclines or Trastuzumab in Patients With Breast Cancer

Lewinter C et al. Eur Heart J. 2022;43(27):2562-2569.

How to Treat Breast Cancer After Childhood Cancer: Management of Oncologic and Cardiovascular Concerns

Blaes AH et al. JACC CardioOncol. 2022;4(1):126-129.

Validity of Estimated Cardiorespiratory Fitness in Patients With Primary Breast Cancer

Michalski M et al. JACC CardioOncol. 2022;4(2):210-219.

Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors: A Cross-Sectional Study

Naaktgeboren WR et al. JACC CardioOncol. 2022;4(2):183-191.

Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study

Greenlee H et al. J Clin Oncol. 2022;40(15):1647-1658.

COVID-19

Innovations in Cardio-oncology Resulting from the COVID-19 Pandemic

Kondapalli L et al. Curr Treat Options Oncol. 2022;23(9):1288-1302.

GI Cancers

Long-Term Cardiac Disease- and Cancer-Associated Mortalities in Patients With Non-Metastatic Stomach Adenocarcinoma Receiving Resection and Chemotherapy: A Large Competing-Risk Population-Based Cohort Study

Huang L et al. World J Oncol. 2022;13(2):69-83.

Guidelines

Clinical Practice Guidelines in Cardio-Oncology

Leong DP et al. Heart Fail Clin. 2022;18(3):489-501.

International Consensus Statement on the Management of Cardiovascular Risk of Bruton's Tyrosine Kinase Inhibitors in CLL

Awan FT et al. Blood Adv. 2022;bloodadvances.2022007938.

Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

Beavers CJ et al. Circulation. 2022;145(15):e811-e838.

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Lyon AR et al. Eur Heart J. 2022:ehac244.

Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update

Giordano SH et al. J Clin Oncol. 2022;40(23):2612-2635.

Haematological Cancers

Cardiotoxicity From Chimeric Antigen Receptor-T Cell Therapy for Advanced Malignancies

Totzeck M et al. Eur Heart J. 2022;43(20):1928-1940.

Cardiovascular Disease in Myeloproliferative Neoplasms: JACC: CardioOncology State-of-the-Art Review

Leiva O et al. JACC CardioOncol. 2022;4(2):166-182.

Cardiovascular Disease Among Patients With AML and CHIP-Related Mutations

Calvillo-Argüelles O et al. JACC CardioOncol. 2022;4(1):38-49.

Miscellaneous

Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study

Florido R et al. J Am Coll Cardiol. 2022;80(1):22-32.

Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies

Chen DY et al. JACC CardioOncol. 2022;4(2):223-234.

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program

Naqash AR et al. J Clin Oncol. 2022;JCO2200369.

Research Quality and Impact of Cardiac Rehabilitation in Cancer Survivors: A Systematic Review and Meta-Analysis

Fakhraei R et al. JACC CardioOncol. 2022;4(2):195-206.

Cardiovascular Adverse Events in Oncology Trials: Understanding and Appreciating the Differences Between Clinical Trial Data and Real-World Reports

Ewer MS et al. Cardiooncology. 2022;8(1):13.

Cardio-Onco-Metabolism: Metabolic Remodelling in Cardiovascular Disease and Cancer

Karlstaedt A et al. Nat Rev Cardiol. 2022;19(6):414-425.

Other Cancers

Does Prostate-Cancer Treatment Place a Strain on the Heart?

Schmidt C et al. Nature. 2022;609(7927):S46-S47.

Radcliffe Content

Radiation-associated Arrhythmias: Putative Pathophysiological Mechanisms, Prevalence, Screening and Management Strategies

Arrhythmia & Electrophysiology Review 2023;12:e24.

A Case of Primary Cardiac B-cell Lymphoma Diagnosed with Cardiac MRI

US Cardiology Review 2023;17:e08.

Ventricular Arrhythmia in Cancer Patients: Mechanisms, Treatment Strategies and Future Avenues

Arrhythmia & Electrophysiology Review 2023;12:e16.

Cancer and Postradiotherapy Cardiotoxicity: How to Face Damage in Women’s Hearts?

European Cardiology Review 2023;18:e08.

Cardio-oncology in 2022

European Cardiology Review 2023;18:e04.

Chest Pain in the Cancer Patient

European Cardiology Review 2022;17:e15.

Review Articles

Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review

Glen C et al. JACC CardioOncol. 2022;4(1):1-18.

The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review

Omland T et al. JACC CardioOncol. 2022;4(1):19-37.

Immune-Checkpoint Inhibitors: Long-Term Implications of Toxicity

Johnson DB et al. Nat Rev Clin Oncol. 2022;19(4):254-267.

An Integrated Approach to Cardioprotection in Lymphomas

Maraldo MV et al. Lancet Haematol. 2022;9(6):e445-e454.

Service Development

Practical Approaches to Build and Sustain a Cardio-Oncology Clinic

Chasouraki A et al. J Cardiovasc Dev Dis. 2022;9(5):158.

Early Access to a Cardio-Oncology Clinic in an Australian Context: A Qualitative Exploration of Patient Experiences

White J et al. Cardiooncology. 2022;8(1):14.